Startup profile · funding coverage
Xlue funding, valuation and investors
Research-stage AI predicting future disease risk from patient medical histories.
Verified company research · funding, investors and latest developments
Keep track of Xlue
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Seed (disclosed; legal close date unverified)
$35M · November 18, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$35M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
seed · United States (Carnegie Mellon origins; current legal headquarters unverified)
Investors in latest funding
Lead: Conviction
Overview
Xlue researches health-state/action AI models for predicting future disease risk from electronic health records and exploring possible trial simulations. Its medical use and pricing are not verified as generally available.
Why Xlue is interesting
CMU spinout disclosed $35M Seed led by Conviction on Nov 18 2026. Promising HealthSAW retrospective data, but no proven prospective clinical outcomes.
Product & use cases
HealthSAW is a research-stage model intended to forecast future diagnoses from records and clinical events, not a verified commercial cancer diagnostic or validated causal-treatment simulator. No published pricing.
- Hospitals: retrospective/prospective studies of disease-risk screening and clinician triage
- Drug developers: exploratory models of trial design and treatment trajectories; actual efficacy unproven
Key facts
- CEO Chenyan Xiong; CMU spinout cofounders include Hao-Ren Yao and Ophir Frieder.
- 2025 CATCH-FM 30k cohort, Forbes-reported later 80k cohort and Protege HealthSAW 2.5k test are distinct studies.
- Research partner hospitals and pharma prospects; no proven widespread clinical rollout or published commercial pricing.
Funding history (newest first)
Seed (disclosed; legal close date unverified)
2026-11-18 $35MSource: Read source · tollbit.forbes.com
Investors in our directory
Funds linked from Xlue's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
In Protege's Oct 2026 2,500-patient, 16-task quasi-double-blind test, HealthSAW reported mean 37% sensitivity at 95% specificity compared with 30% XGBoost and 26.5% frontier model. Task-specific fine-tuning differs. This is not prospective efficacy; clinical false positives and workflow need validation.
-
TRACER EHR prediction model adjacent
Academic prediction research with health system external validation.
-
Epic clinical decision-support ecosystem incumbent
Native EHR distribution and clinical workflows; no verified direct comparison.
-
Tempus AI adjacent
Oncology data, diagnostics and analytics: different commercial product set.
-
Knit Health adjacent
Healthcare-model research on clinical actions; distinct benchmarks.
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Xlue
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.